Compass Therapeutics reports tovecimig Phase 2/3 COMPANION-002 met primary endpoint; BLA filing planned

Compass Therapeutics, Inc.

Tovecimig + paclitaxel achieved ORR 18.0% vs 5.3% paclitaxel alone (p=0.0228); median PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001).
OS analysis confounded by 54% crossover; post-hoc subset shows median OS 12.8 mo for crossover patients vs 6.1 mo for no-crossover (HR=0.54, p=0.04).
Cash and marketable securities $195M as of Q1 2026; runway into 2028. FDA meeting expected Q3 2026, BLA filing late 2026, potential approval 2H 2027.
Pipeline includes CTX-8371 (PD-1xPD-L1) with deep responses in TNBC, HL, NSCLC; CTX-471 (CD137) Phase 2 in NCAM+ tumors mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.